Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors

NCT01222546 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: CH5132799

Sponsor

Chugai Pharma Europe Ltd.